세계의 T세포 림프종 시장 규모, 점유율 및 동향 분석 : 유형별, 치료법별, 지역별, 전망 및 예측(2024-2031년)
Global T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Regional Outlook and Forecast, 2024 - 2031
상품코드:1529162
리서치사:KBV Research
발행일:2024년 08월
페이지 정보:영문 208 Pages
라이선스 & 가격 (부가세 별도)
한글목차
T세포 림프종 시장 규모는 예측 기간 동안 8.5%의 연평균 복합 성장률(CAGR)로 성장하여 2031년까지 37억 달러에 달할 것으로 예상됩니다.
그러나 표적치료제, 면역치료제, 줄기세포 이식 등 첨단 림프종 치료법은 개발, 제조, 투여에 많은 비용이 소요되는 경우가 많습니다. 높은 치료비는 이러한 림프종에 대한 새로운 치료법을 개발하는 제약회사에게 시장 진입 장벽이 될 수 있습니다. 결론적으로, 높은 치료 비용과 의료 서비스의 높은 비용은 시장 성장을 저해하고 있습니다.
대면 진료의 제한, 코로나19 임상시험의 우선순위 결정, 물류 문제 등으로 인해 연구 개발의 진척이 지연되고 있습니다. 전 세계 공급망의 혼란으로 인해 T세포 림프종 치료에 필요한 필수 의약품, 지지 요법 및 의료용품의 수급이 어려워졌습니다. 이로 인해 환자들을 지속적으로 치료하는 데 어려움을 겪었습니다. 팬데믹 기간 동안 경제적 불확실성과 의료 자원의 재분배로 인해 의료 시스템과 환자의 재정적 자원이 압박을 받았으며, T세포 림프종에 대한 전문적인 치료와 고가의 치료에 대한 접근이 제한되어 의료 접근성 격차가 심화되었을 수 있습니다. 이처럼 코로나19 팬데믹은 시장에 부정적인 영향을 미쳤습니다.
유형별 전망
유형에 따라 T 세포 림프종 시장은 말초성 및 림프 모세포 성으로 나뉘며, 2023년에는 림프 모세포 성 부문이 T 세포 림프종 시장 매출 점유율의 35%를 차지했으며, T 세포 급성 림프 모세포 성 백혈병(T-ALL)을 포함한 T 세포 림프종은 비교적 드물지만 공격적인 암입니다, 종종 공격적인 암입니다. 빠른 진행과 심각성으로 인해 신속하고 효과적인 치료가 필요하며, 특정 치료법에 대한 수요가 증가하고 있습니다.
치료의 전망
치료 방법에 따라 시장은 방사선 요법, 화학 요법, 면역 요법, 줄기 세포 이식 및 기타로 분류되며, 2023년 방사선 요법 부문은 시장에서 26%의 매출 점유율을 차지했습니다. 방사선 요법은 고에너지 방사선을 종양 부위에 직접 조사하여 국소 림프종을 치료합니다.
목차
제1장 시장 범위와 조사 방법
시장의 정의
목적
시장 범위
세분화
조사 방법
제2장 시장 요람
주요 하이라이트
제3장 시장 개요
서론
개요
시장 구성과 시나리오
시장에 영향을 미치는 주요 요인
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
시장이 해결해야 할 과제
Porter의 Five Forces 분석
제4장 세계의 T세포 림프종 시장 : 유형별
세계의 말초성 시장 : 지역별
세계의 림프구성 시장 : 지역별
제5장 세계의 T세포 림프종 시장 : 요법별
세계의 화학요법 시장 : 지역별
세계의 방사선 요법 시장 : 지역별
세계의 면역치료 시장 : 지역별
세계의 줄기세포 이식 시장 : 지역별
세계의 기타 시장 : 지역별
제6장 세계의 T세포 림프종 시장 : 지역별
북미
북미 시장 : 국가별
미국
캐나다
멕시코
기타 북미
유럽
유럽 시장 : 국가별
독일
영국
프랑스
러시아
스페인
이탈리아
기타 유럽
아시아태평양
아시아태평양 시장 : 국가별
중국
일본
인도
한국
싱가포르
말레이시아
기타 아시아태평양
라틴아메리카/중동 및 아프리카
라틴아메리카/중동 및 아프리카 시장 : 국가별
브라질
아르헨티나
아랍에미리트(UAE)
사우디아라비아
남아프리카공화국
나이지리아
기타 라틴아메리카/중동 및 아프리카
제7장 기업 개요
Bristol Myers Squibb Company
Daiichi Sankyo Company, Limited
Eisai Co, Ltd.
Acrotech Biopharma Inc(Aurobindo Pharma USA)
Shenzhen Chipscreen Biosciences Co, Ltd.
Citius Pharmaceuticals, Inc
Genor Biopharma Co Ltd
Innate Pharma SA
Dizal Pharmaceutical Co Ltd.
제8장 T세포 림프종 시장을 위한 성공 필수 조건
LSH
영문 목차
영문목차
The Global T-cell Lymphoma Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 8.5% CAGR during the forecast period.
There is a noticeable increase in the incidence of these lymphomas across various countries in the Asia-Pacific region. This rise can be attributed to changing demographics, environmental factors, lifestyle changes, and improved diagnostic capabilities, leading to better detection and reporting. Consequently, the Asia Pacific region would acquire nearly 28% of the total market share by 2031.
Improved understanding of these lymphomas among healthcare professionals leads to earlier disease detection. In addition, advances in diagnostic technologies, such as molecular profiling, flow cytometry, and imaging techniques, enhance the accuracy and reliability of these lymphoma diagnosis. Therefore, increasing disease awareness and diagnosis is driving the market's growth. Additionally, Higher healthcare expenditure typically leads to improved access to healthcare services, including diagnostic tests, specialist consultations, and advanced treatment options for these lymphomas. Furthermore, much healthcare spending goes towards oncology research and development (R&D), including these lymphomas. Thus, rising healthcare expenditure globally is propelling the growth of the market.
However, Advanced treatment modalities for these lymphomas, such as targeted therapies, immunotherapies, and stem cell transplants, are often costly to develop, manufacture, and administer. High treatment costs can create barriers to market access for pharmaceutical companies developing new therapies for these lymphomas. In conclusion, the high cost of treatment and healthcare services hinders the market's growth.
Restrictions on in-person visits, prioritization of COVID-19 trials, and logistical challenges hindered the progress of research and development efforts. Disruptions in global supply chains affected the availability of essential medications, supportive care therapies, and medical supplies needed to treat T-cell lymphomas. This posed challenges in maintaining continuity of care for patients. Economic uncertainties and healthcare resource reallocations during the pandemic strained healthcare systems and patients' financial resources. Access to specialized care and expensive treatments for T-cell lymphomas may have been limited, exacerbating disparities in healthcare access. Thus, the COVID-19 pandemic had a negative impact on the market.
Type Outlook
Based on type, the T-cell lymphoma market is divided into peripheral and lymphoblastic. In 2023, the lymphoblastic segment attained 35% revenue share in the T-cell lymphoma Market. T-cell lymphomas, including T-cell acute lymphoblastic leukemia (T-ALL), are relatively rare but often aggressive cancers. Their rapid progression and severity necessitate prompt and effective treatment, increasing the demand for specific therapies.
Therapy Outlook
On the basis of therapy, the market is segmented into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others. In 2023, the radiotherapy segment attained a 26% revenue share in the market. Radiotherapy treats localized lymphomas by delivering high-energy radiation directly to the tumor site.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 39% revenue share in the market in 2023. North America, particularly the United States and Canada, has one of the highest healthcare expenditures globally. This allows for greater affordability and accessibility to advanced diagnostic tools, treatments, and therapies for T-cell lymphomas.
List of Key Companies Profiled
Bristol Myers Squibb Company
Daiichi Sankyo Company, Limited
Eisai Co., Ltd
Acrotech Biopharma Inc. (Aurobindo Pharma USA)
Shenzhen Chipscreen Biosciences Co., Ltd.
Citius Pharmaceuticals, Inc.
Genor Biopharma Co. Ltd.
Innate Pharma SA
Dizal Pharmaceutical Co. Ltd.
Global T-cell Lymphoma Market Report Segmentation
By Type
Peripheral
Cutaneous T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angio-immuno-blastic T-cell Lymphoma
Others
Lymphoblastic
By Therapy
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
By Geography
North America
US
Canada
Mexico
Rest of North America
Europe
Germany
UK
France
Russia
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific
LAMEA
Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global T-cell Lymphoma Market, by Type
1.4.2 Global T-cell Lymphoma Market, by Therapy
1.4.3 Global T-cell Lymphoma Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Global T-cell Lymphoma Market by Type
4.1 Global Peripheral Market by Region
4.2 Global T-cell Lymphoma Market by Peripheral Type
4.2.1 Global Cutaneous T-cell Lymphoma Market by Region
4.2.2 Global Anaplastic Large Cell Lymphoma Market by Region
4.2.3 Global Angio-immuno-blastic T-cell Lymphoma Market by Region
4.2.4 Global Others Market by Region
4.3 Global Lymphoblastic Market by Region
Chapter 5. Global T-cell Lymphoma Market by Therapy
5.1 Global Chemotherapy Market by Region
5.2 Global Radiotherapy Market by Region
5.3 Global Immunotherapy Market by Region
5.4 Global Stem Cell Transplantation Market by Region
5.5 Global Others Market by Region
Chapter 6. Global T-cell Lymphoma Market by Region
6.1 North America T-cell Lymphoma Market
6.1.1 North America T-cell Lymphoma Market by Type
6.1.1.1 North America Peripheral Market by Country
6.1.1.2 North America T-cell Lymphoma Market by Peripheral Type
6.1.1.2.1 North America Cutaneous T-cell Lymphoma Market by Country
6.1.1.2.2 North America Anaplastic Large Cell Lymphoma Market by Country
6.1.1.2.3 North America Angio-immuno-blastic T-cell Lymphoma Market by Country
6.1.1.2.4 North America Others Market by Country
6.1.1.3 North America Lymphoblastic Market by Country
6.1.2 North America T-cell Lymphoma Market by Therapy
6.1.2.1 North America Chemotherapy Market by Country
6.1.2.2 North America Radiotherapy Market by Country
6.1.2.3 North America Immunotherapy Market by Country
6.1.2.4 North America Stem Cell Transplantation Market by Country
6.1.2.5 North America Others Market by Country
6.1.3 North America T-cell Lymphoma Market by Country
6.1.3.1 US T-cell Lymphoma Market
6.1.3.1.1 US T-cell Lymphoma Market by Type
6.1.3.1.2 US T-cell Lymphoma Market by Therapy
6.1.3.2 Canada T-cell Lymphoma Market
6.1.3.2.1 Canada T-cell Lymphoma Market by Type
6.1.3.2.2 Canada T-cell Lymphoma Market by Therapy
6.1.3.3 Mexico T-cell Lymphoma Market
6.1.3.3.1 Mexico T-cell Lymphoma Market by Type
6.1.3.3.2 Mexico T-cell Lymphoma Market by Therapy
6.1.3.4 Rest of North America T-cell Lymphoma Market
6.1.3.4.1 Rest of North America T-cell Lymphoma Market by Type
6.1.3.4.2 Rest of North America T-cell Lymphoma Market by Therapy
6.2 Europe T-cell Lymphoma Market
6.2.1 Europe T-cell Lymphoma Market by Type
6.2.1.1 Europe Peripheral Market by Country
6.2.1.2 Europe T-cell Lymphoma Market by Peripheral Type
6.2.1.2.1 Europe Cutaneous T-cell Lymphoma Market by Country
6.2.1.2.2 Europe Anaplastic Large Cell Lymphoma Market by Country
6.2.1.2.3 Europe Angio-immuno-blastic T-cell Lymphoma Market by Country
6.2.1.2.4 Europe Others Market by Country
6.2.1.3 Europe Lymphoblastic Market by Country
6.2.2 Europe T-cell Lymphoma Market by Therapy
6.2.2.1 Europe Chemotherapy Market by Country
6.2.2.2 Europe Radiotherapy Market by Country
6.2.2.3 Europe Immunotherapy Market by Country
6.2.2.4 Europe Stem Cell Transplantation Market by Country
6.2.2.5 Europe Others Market by Country
6.2.3 Europe T-cell Lymphoma Market by Country
6.2.3.1 Germany T-cell Lymphoma Market
6.2.3.1.1 Germany T-cell Lymphoma Market by Type
6.2.3.1.2 Germany T-cell Lymphoma Market by Therapy
6.2.3.2 UK T-cell Lymphoma Market
6.2.3.2.1 UK T-cell Lymphoma Market by Type
6.2.3.2.2 UK T-cell Lymphoma Market by Therapy
6.2.3.3 France T-cell Lymphoma Market
6.2.3.3.1 France T-cell Lymphoma Market by Type
6.2.3.3.2 France T-cell Lymphoma Market by Therapy
6.2.3.4 Russia T-cell Lymphoma Market
6.2.3.4.1 Russia T-cell Lymphoma Market by Type
6.2.3.4.2 Russia T-cell Lymphoma Market by Therapy
6.2.3.5 Spain T-cell Lymphoma Market
6.2.3.5.1 Spain T-cell Lymphoma Market by Type
6.2.3.5.2 Spain T-cell Lymphoma Market by Therapy
6.2.3.6 Italy T-cell Lymphoma Market
6.2.3.6.1 Italy T-cell Lymphoma Market by Type
6.2.3.6.2 Italy T-cell Lymphoma Market by Therapy
6.2.3.7 Rest of Europe T-cell Lymphoma Market
6.2.3.7.1 Rest of Europe T-cell Lymphoma Market by Type
6.2.3.7.2 Rest of Europe T-cell Lymphoma Market by Therapy
6.3 Asia Pacific T-cell Lymphoma Market
6.3.1 Asia Pacific T-cell Lymphoma Market by Type
6.3.1.1 Asia Pacific Peripheral Market by Country
6.3.1.2 Asia Pacific T-cell Lymphoma Market by Peripheral Type
6.3.1.2.1 Asia Pacific Cutaneous T-cell Lymphoma Market by Country
6.3.1.2.2 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country
6.3.1.2.3 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country
6.3.1.2.4 Asia Pacific Others Market by Country
6.3.1.3 Asia Pacific Lymphoblastic Market by Country
6.3.2 Asia Pacific T-cell Lymphoma Market by Therapy
6.3.2.1 Asia Pacific Chemotherapy Market by Country
6.3.2.2 Asia Pacific Radiotherapy Market by Country
6.3.2.3 Asia Pacific Immunotherapy Market by Country
6.3.2.4 Asia Pacific Stem Cell Transplantation Market by Country
6.3.2.5 Asia Pacific Others Market by Country
6.3.3 Asia Pacific T-cell Lymphoma Market by Country
6.3.3.1 China T-cell Lymphoma Market
6.3.3.1.1 China T-cell Lymphoma Market by Type
6.3.3.1.2 China T-cell Lymphoma Market by Therapy
6.3.3.2 Japan T-cell Lymphoma Market
6.3.3.2.1 Japan T-cell Lymphoma Market by Type
6.3.3.2.2 Japan T-cell Lymphoma Market by Therapy
6.3.3.3 India T-cell Lymphoma Market
6.3.3.3.1 India T-cell Lymphoma Market by Type
6.3.3.3.2 India T-cell Lymphoma Market by Therapy
6.3.3.4 South Korea T-cell Lymphoma Market
6.3.3.4.1 South Korea T-cell Lymphoma Market by Type
6.3.3.4.2 South Korea T-cell Lymphoma Market by Therapy
6.3.3.5 Singapore T-cell Lymphoma Market
6.3.3.5.1 Singapore T-cell Lymphoma Market by Type
6.3.3.5.2 Singapore T-cell Lymphoma Market by Therapy
6.3.3.6 Malaysia T-cell Lymphoma Market
6.3.3.6.1 Malaysia T-cell Lymphoma Market by Type
6.3.3.6.2 Malaysia T-cell Lymphoma Market by Therapy
6.3.3.7 Rest of Asia Pacific T-cell Lymphoma Market
6.3.3.7.1 Rest of Asia Pacific T-cell Lymphoma Market by Type
6.3.3.7.2 Rest of Asia Pacific T-cell Lymphoma Market by Therapy
6.4 LAMEA T-cell Lymphoma Market
6.4.1 LAMEA T-cell Lymphoma Market by Type
6.4.1.1 LAMEA Peripheral Market by Country
6.4.1.2 LAMEA T-cell Lymphoma Market by Peripheral Type
6.4.1.2.1 LAMEA Cutaneous T-cell Lymphoma Market by Country
6.4.1.2.2 LAMEA Anaplastic Large Cell Lymphoma Market by Country
6.4.1.2.3 LAMEA Angio-immuno-blastic T-cell Lymphoma Market by Country
6.4.1.2.4 LAMEA Others Market by Country
6.4.1.3 LAMEA Lymphoblastic Market by Country
6.4.2 LAMEA T-cell Lymphoma Market by Therapy
6.4.2.1 LAMEA Chemotherapy Market by Country
6.4.2.2 LAMEA Radiotherapy Market by Country
6.4.2.3 LAMEA Immunotherapy Market by Country
6.4.2.4 LAMEA Stem Cell Transplantation Market by Country
6.4.2.5 LAMEA Others Market by Country
6.4.3 LAMEA T-cell Lymphoma Market by Country
6.4.3.1 Brazil T-cell Lymphoma Market
6.4.3.1.1 Brazil T-cell Lymphoma Market by Type
6.4.3.1.2 Brazil T-cell Lymphoma Market by Therapy
6.4.3.2 Argentina T-cell Lymphoma Market
6.4.3.2.1 Argentina T-cell Lymphoma Market by Type
6.4.3.2.2 Argentina T-cell Lymphoma Market by Therapy
6.4.3.3 UAE T-cell Lymphoma Market
6.4.3.3.1 UAE T-cell Lymphoma Market by Type
6.4.3.3.2 UAE T-cell Lymphoma Market by Therapy
6.4.3.4 Saudi Arabia T-cell Lymphoma Market
6.4.3.4.1 Saudi Arabia T-cell Lymphoma Market by Type
6.4.3.4.2 Saudi Arabia T-cell Lymphoma Market by Therapy
6.4.3.5 South Africa T-cell Lymphoma Market
6.4.3.5.1 South Africa T-cell Lymphoma Market by Type
6.4.3.5.2 South Africa T-cell Lymphoma Market by Therapy
6.4.3.6 Nigeria T-cell Lymphoma Market
6.4.3.6.1 Nigeria T-cell Lymphoma Market by Type
6.4.3.6.2 Nigeria T-cell Lymphoma Market by Therapy
6.4.3.7 Rest of LAMEA T-cell Lymphoma Market
6.4.3.7.1 Rest of LAMEA T-cell Lymphoma Market by Type
6.4.3.7.2 Rest of LAMEA T-cell Lymphoma Market by Therapy
Chapter 7. Company Profiles
7.1 Bristol Myers Squibb Company
7.1.1 Company Overview
7.1.2 SWOT Analysis
7.2 Daiichi Sankyo Company, Limited
7.2.1 Company Overview
7.2.2 SWOT Analysis
7.3 Eisai Co., Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 SWOT Analysis
7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
7.4.1 Company Overview
7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
7.5.1 Company Overview
7.6 Citius Pharmaceuticals, Inc.
7.6.1 Company Overview
7.6.2 Recent strategies and developments:
7.6.2.1 Trials and Approvals:
7.7 Genor Biopharma Co. Ltd
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Innate Pharma SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.9 Dizal Pharmaceutical Co. Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Trials and Approvals:
Chapter 8. Winning imperatives for T-cell Lymphoma Market
